Ex-dividend: ONGC (Rs 18 per share), HPCL (Rs 6 per share) and GAIL (Rs 5.50 per share)
Oil Min: Extend 7 years tax holiday to Gail under section 80 1B Recognize discounts given by ONGC to OMCs as legitimate deductions
NSE bars fresh F&O positions in IFCI as 95% of marketwide limit reached (Parsvnath already in curb, NDTV out of it)
In T2T from January 2: BPL, Crest Animation, Jain Studios and RPG Cables
Triton Corp to buy Maple eSolutions from Haryana Fibres
Mid-day Multimedia reacquires title/ownership of Delhi Mid Day
Panoramic Universal to foray into realty biz
SBI hikes PLR to 11.50% from 11% effective today
Maharashtra Seamless bags Rs 474 crore (Rs 4.74 billion) order from ONGC
BPCL board declares 60% interim dividend
SEBI disposes case against Essar Oil on non-receipt of debenture interest by shareholders after 1995 public issue of optional fully convertible debentures
PM asks Commerce Minister to prepare Cabinet note on allowing FDI in retail areas like stationery, electronics and sports goods
Essar makes offer to buy Hutchison group's 67% stake in Hutch-Essar at an estimated EV of USD17-18 billion - ET
M&M,Tafe eye Actis' 29% stake in Punjab Tractors - ET
Bharti plans hiving off telecom Infrastructure into 4 company to attract strategic and financial investors - ET
3i Infotech eyes cos with products in Insurance - ET
Power traiffs likely to go up further as government is planning to revise royalty rates on Coal - ET
Videocon seeks 13% discount on agreed price for aqcuring south koreas sick daewoo electronics (agreed price of Rs 3200 crore) - BL
Gail set for unbundling of marketing, transmission biz - BL
Dr Reddys anti-diabetic drug enters phase 1 trials in Netherlands - BL
Saregama India in talks with motorola ,sony ericsson to market its music tracks - BL
Amtek Auto seeks buyouts in US, Europe with turnover of upto USD 700 million in the casting and forging segments: DNA
Dr Reddys Laboratories: DRL gets USFDA approval for generic Zofran tablets: Sources Zofran market for injectibles & tablets seen at USD 850 million -- Alert DRL expects USD 40-50 million of revenue from 6-month Zofran exclusivity - Alert Zofran is GSK's anti-nausea drug - Alert
